ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Memantine

Also written as “Memantine Hydrochloride (HCl)”, “memantine” and “memantine HCl”.

Its studies are mostly in Alzheimer Disease · Autistic Disorder · Autism Spectrum Disorder · Glaucoma, Open-Angle · Cancer Pain, led by 7 companies.

Drug pageMemantine: every studyMany companies study it; this page follows only the 27 they lead. All 198 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Jun 6, 200627 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVie130 open or runningphase 4since Jun 6, 2006Dec 1, 2004none ahead
H. Lundbeckits history only60 open or runningphase 4since Mar 3, 2009Mar 3, 2009none ahead
Merz Pharmaits history only40 open or runningphase 4since Mar 27, 2008Feb 14, 2008none ahead
Carnot Laboratoriesits history only10 open or runningphase 4since Feb 11, 2026Feb 11, 2026none ahead
Gedeon Richter Plc.its history only10 open or runningphase 1since Nov 15, 2013Nov 15, 2013none ahead
Geropharmits history only10 open or runningphase 1since Apr 18, 2017Apr 18, 2017none ahead
Mendel AIits history only10 open or runningphase 3since Jan 30, 2021Jan 30, 2021none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of AbbVie only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 1, 2004First study: phase 2 study in SchizophreniaFirst studyNCT00097942 · 138 enrolled · United States
  2. Dec 1, 2004Phase 3 study in Alzheimer DiseaseNCT00097916 · 34 enrolled · United States
  3. Mar 24, 2005Phase 2 study in Bipolar DisorderNCT00106405 · 35 enrolled · United States
  4. Aug 31, 2005Phase 3 study in Glaucoma, Open-AngleNCT00141882 · 1,119 enrolled
  5. Sep 9, 2005Phase 3 study in Glaucoma, Open-AngleNCT00168350 · 1,179 enrolled
  6. May 3, 2006Phase 3 study in Alzheimer DiseaseNCT00322153 · 677 enrolled · United States, Argentina, Chile and more
  7. Jun 6, 2006Phase 4 study in Alzheimer DiseaseNCT00334906 · 75 enrolled · United States
  8. May 2, 2007Phase 4 study in Alzheimer DiseaseNCT00469456 · 265 enrolled · Australia, New Zealand, South Africa
  9. Mar 30, 2009Phase 2 study in Autistic DisorderNCT00872898 · 124 enrolled · United States
  10. May 3, 20123 phase 2 studiesNCT01592786, NCT01592773, NCT01592747
  11. Nov 26, 2013Phase 2 study in Autistic DisorderNCT01999894 · 102 enrolled · United States

TargetBeta

“Glutamate [NMDA] receptor negative allosteric modulator”ChEMBL 37, by rule

Other programs on the same 7 targets

ProgramCompanyFurthest phaseStudies
EsketamineruleJohnson & Johnsonphase 451

Studies

All 13 AbbVie leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01999894Autistic Disorder · United States2CompletedFeb 2013102
NCT01592786Autism Spectrum Disorder · United States, Australia, Belgium and more2CompletedJul 2013906
NCT01592773Autism Spectrum Disorder · United States, Belgium, Canada and more2TerminatedJan 2014747
NCT01592747Autistic Disorder · United States, Belgium, Colombia and more2CompletedSep 2013479
NCT00872898Autistic Disorder · United States2CompletedAug 2012124
NCT00469456Alzheimer Disease · Australia, New Zealand, South Africa4CompletedNov 2008265
NCT00334906Alzheimer Disease · United States4CompletedNov 200775
NCT00322153Alzheimer Disease · United States, Argentina, Chile and more3CompletedOct 2007677
NCT00168350Glaucoma, Open-Angle3CompletedSep 20061,179
NCT00141882Glaucoma, Open-Angle3CompletedJan 20061,119
NCT00106405Bipolar Disorder · United States2CompletedNov 200535
NCT00097942Schizophrenia · United States2CompletedSep 2005138
NCT00097916Alzheimer Disease · United States3CompletedApr 200634

How it is read

Names in the registry

  • “Memantine”, 11 entries
  • “Memantine Hydrochloride (HCl)”, 4 entries
  • “memantine”, 3 entries
  • “memantine HCl”, 3 entries
  • “Memantine HCl”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.